We are live on ! Find out more
VA

VR Adviser Portfolio holdings

AUM $2.68B
1-Year Est. Return 422.73%
This Fund
S&P 500
This Quarter Est. Return
+29.04%
1 Year Est. Return
+422.73%
3 Year Est. Return
+1,447.09%
5 Year Est. Return
+3,249.52%
10 Year Est. Return
–
AUM
$922M
AUM Growth
+$242M
Cap. Flow
+$283M
Cap. Flow %
30.74%
Top 10 Hldgs %
73.15%
Holding
32
New
7
Increased
7
Reduced
5
Closed
4

Top Buys

Rank Stock Value
1
TIL icon
Instil Bio
TIL
+$176M
2
CGEM icon
Cullinan Oncology
CGEM
+$47.7M
3
ACRS icon
Aclaris Therapeutics
ACRS
+$34.5M
4
PHVS icon
Pharvaris
PHVS
+$28.4M
5
VTGN icon
VistaGen Therapeutics
VTGN
+$15.4M

Top Sells

Rank Stock Value
1
KROS icon
Keros Therapeutics
KROS
+$19M
2
ALT icon
Altimmune
ALT
+$16.2M
3
SURF
Surface Oncology, Inc. Common Stock
SURF
+$13.3M
4
SNDX icon
Syndax Pharmaceuticals
SNDX
+$11.8M
5
GRTX
Galera Therapeutics, Inc. Common Stock
GRTX
+$9.39M

Sector Composition

Rank Sector Weight
1 Healthcare 89.82%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TIL icon
1
Instil Bio
TIL
$48.3M
$172M 18.68%
+343,254
New +$176M
CNST
2
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
$94M 10.19%
4,016,873
– –
ACRS icon
3
Aclaris Therapeutics
ACRS
$726M
$93.8M 10.17%
3,720,582
+1,765,650
+90% +$34.5M
OLMA icon
4
Olema Pharmaceuticals
OLMA
$1B
$51M 5.53%
1,536,193
– –
ALT icon
5
Altimmune
ALT
$552M
$49.5M 5.37%
3,500,000
-1,000,000
-22% -$16.2M
CGEM icon
6
Cullinan Oncology
CGEM
$1.01B
$49M 5.32%
+1,176,145
New +$47.7M
KNTE
7
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
$45.9M 4.98%
1,473,014
– –
TRIL
8
DELISTED
Trillium Therapeutics Inc.
TRIL
$43.4M 4.71%
4,040,000
– –
MRNS
9
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$40.9M 4.44%
2,641,809
+52,868
+2% +$765K
VTGN icon
10
VistaGen Therapeutics
VTGN
$9.89M
$34.7M 3.77%
543,420
+231,420
+74% +$15.4M
LONA
11
LeonaBio Inc
LONA
$66.3M
$31.1M 3.38%
169,162
– –
RLMD icon
12
Relmada Therapeutics
RLMD
$557M
$30M 3.26%
853,206
+184,766
+28% +$6.46M
CLDX icon
13
Celldex Therapeutics
CLDX
$2.99B
$25.6M 2.77%
1,240,610
+440,610
+55% +$10.1M
PHVS icon
14
Pharvaris
PHVS
$2.28B
$25.3M 2.75%
+902,882
New +$28.4M
KROS icon
15
Keros Therapeutics
KROS
$199M
$22.9M 2.49%
372,306
-300,000
-45% -$19M
EPIX
16
DELISTED
ESSA Pharma
EPIX
$18.2M 1.97%
+625,754
New +$14.5M
KURA icon
17
Kura Oncology
KURA
$800M
$16.3M 1.76%
575,000
– –
SNDX icon
18
Syndax Pharmaceuticals
SNDX
$1.69B
$13.2M 1.44%
591,782
-523,473
-47% -$11.8M
ACET icon
19
Adicet Bio
ACET
$85.2M
$13.1M 1.42%
+62,500
New +$14.3M
APTO
20
DELISTED
Aptose Biosciences, Inc.
APTO
$9.59M 1.04%
+3,568
New +$7.07M
COGT icon
21
Cogent Biosciences
COGT
$6.65B
$9.56M 1.04%
1,088,817
– –
ALGS icon
22
Aligos Therapeutics
ALGS
$26.2M
$9.29M 1.01%
16,335
+139
+0.9% +$92.5K
EYPT icon
23
EyePoint Inc
EYPT
$1.03B
$7.11M 0.77%
+700,000
New +$7.88M
TNGX icon
24
Tango Therapeutics
TNGX
$4.43B
$5.56M 0.6%
500,000
– –
MTCR
25
DELISTED
Metacrine, Inc. Common Stock
MTCR
$4.22M 0.46%
680,000
-13,673
-2% -$121K
1
2

Similar funds

MMEA
Main Management ETF Advisors San Francisco, California $2.68B AUM 24.27% 1-Year Est. Return
WGI
Westwood Global Investments Boston, Massachusetts $2.68B AUM 76.4% 1-Year Est. Return
TCAM
Turtle Creek Asset Management Toronto, Ontario, Canada $2.67B AUM 0.64% 1-Year Est. Return
SFI
Susquehanna Fundamental Investments Bala Cynwyd, Pennsylvania $2.67B AUM 21.74% 1-Year Est. Return
HC
Henshaw Capital Woburn, Massachusetts $2.7B AUM 29.67% 1-Year Est. Return
CI
Capital International Los Angeles, California $2.7B AUM 31.08% 1-Year Est. Return
PCA
Pallas Capital Advisors Braintree, Massachusetts $2.66B AUM 22.31% 1-Year Est. Return
LP
Longaeva Partners Chicago, Illinois $2.7B AUM 37.16% 1-Year Est. Return

VR Adviser's Q1 2021 Portfolio in Review

As of Q1 2021, VR Adviser held 32 positions worth $922M, up 36% from $680M the previous quarter. Its ten largest holdings account for 73% of the portfolio.

VR Adviser deployed $283M of net new capital in Q1 2021, opening 7 new positions and adding to 7 existing holdings. Its largest new stake was Instil Bio: 343,254 shares worth $172M.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, up from 87% a quarter earlier.

On the sell side, the largest reduction was Keros Therapeutics, an estimated $19M trimmed.

  • VR Adviser's largest Q1 2021 buy was Instil Bio: 343,254 shares worth $172M.
  • VR Adviser added most to Aclaris Therapeutics in Q1 2021, an estimated $34.5M increase.
  • VR Adviser's biggest Q1 2021 reduction was Keros Therapeutics, cutting an estimated $19M.
  • VR Adviser fully exited Surface Oncology, Inc. Common Stock in Q1 2021, selling an estimated $13.3M.
  • VR Adviser's ten largest holdings make up 73% of its $922M portfolio in Q1 2021.
  • VR Adviser opened 7 new positions and closed 4 in Q1 2021.
  • VR Adviser's portfolio value rose 36% quarter-over-quarter to $922M.

Based on VR Adviser's 13F filing for Q1 2021, filed 14 May 2021.